Quantcast

Latest Everolimus Stories

2011-08-30 15:05:33

Lower rate of stent thrombosis found with second-generation drug-eluting stent than with bare metal stent The second generation drug-eluting stent Xience V performs well in patients having primary PCI for ST elevation myocardial infarction, and has a better safety profile than that of bare metal stents, according to results of the EXAMINATION (Evaluation of Xience-V stent in Acute Myocardial INfArcTION) trial. The study was a randomised controlled trial with an "all-comers" design to...

2011-08-30 12:28:35

Results from the Bern-Rotterdam cohort study Results of the independently-funded Bern-Rotterdam cohort study provide robust evidence of an "important" reduction in overall and very late stent thrombosis. The reduction in incidence was found when a newer generation everolimus-eluting stent (EES) was compared with early generation drug-eluting stents (DES) at long-term follow-up. "The near elimination of stent thrombosis observed between one and four years after implantation shows that...

2011-08-16 08:00:00

ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the first patient in Japan has been treated with the ABSORB(TM) bioresorbable vascular scaffold (BVS) as part of the ABSORB EXTEND clinical trial. Abbott's BVS restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. The device received CE...

2011-07-25 08:06:00

ATLANTA, July 25, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that its MassTrak(TM) Immunosuppressants XE Kit is now CE-marked in accordance with the IVD Directive 98/79/EC, for the quantitative measurement of the immunosuppressive drugs tacrolimus (FK506;Prograf®) in liver and kidney transplant patients and everolimus (Certican®) in adult kidney and cardiac transplant patients from human whole blood samples as an aid in the...

2011-07-08 00:19:00

EAST HANOVER, N.J., July 8, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)(1,2,6). This study, the largest prospective clinical trial to date...

2011-06-01 00:24:00

EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). These data underscore the company's commitment to developing treatments to improve the lives of patients with cancer. "Through our commitment to R&D and collaborations with the scientific and patient communities,...

2011-05-25 06:00:00

NATICK, Mass., May 25, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its 2.25 mm PROMUS(®) Everolimus-Eluting Coronary Stent System for use in vessels as small as 2.25 mm in diameter. The Company plans to immediately launch the product in the U.S. The PROMUS Stent features a thin-strut, open-cell design to allow for excellent flexibility and...

2011-05-24 15:41:00

ABBOTT PARK, Ill., May 24, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has received U.S. Food and Drug Administration (FDA) approval for the XIENCE nano(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease in small vessels. XIENCE nano, which is based on the same platform as the XIENCE V® Everolimus Eluting Coronary Stent System, offers physicians in the United States a new option for treating patients with coronary...

2011-05-20 04:00:00

NATICK, Mass. and PARIS, May 20, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced 12-month results from its PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element(TM) Everolimus-Eluting Platinum Chromium Stent System in treating small vessel coronary disease. The study is a global, prospective, single-arm, subtrial of the PLATINUM clinical program. It compares the PROMUS Element Stent (2.25 mm)...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related